Total Payments
$87,575
2024 Payments
$30,487
Companies
14
Transactions
34
Medicare Patients
1,044
Medicare Billing
$164,134
Payment Breakdown by Category
Consulting$85,617 (97.8%)
Travel$1,623 (1.9%)
Food & Beverage$304.99 (0.3%)
Education$30.43 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $85,617 | 14 | 97.8% |
| Travel and Lodging | $1,623 | 6 | 1.9% |
| Food and Beverage | $304.99 | 11 | 0.3% |
| Education | $30.43 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $23,075 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $15,070 | 2 | $0 (2024) |
| BeiGene USA, Inc. | $10,791 | 1 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $9,494 | 2 | $0 (2024) |
| Merck Sharp & Dohme LLC | $7,894 | 8 | $0 (2024) |
| Acrotech Biopharma Inc. | $5,850 | 1 | $0 (2023) |
| Janssen Research & Development, LLC | $5,525 | 1 | $0 (2024) |
| TG Therapeutics, Inc. | $5,400 | 2 | $0 (2022) |
| Eli Lilly and Company | $4,200 | 1 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $121.99 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,487 | 13 | E.R. Squibb & Sons, L.L.C. ($9,494) |
| 2023 | $19,560 | 3 | AstraZeneca Pharmaceuticals LP ($7,535) |
| 2022 | $33,121 | 6 | GlaxoSmithKline, LLC. ($16,900) |
| 2021 | $4,212 | 2 | Eli Lilly and Company ($4,200) |
| 2019 | $11.96 | 1 | PFIZER INC. ($11.96) |
| 2018 | $122.36 | 2 | Novartis Pharmaceuticals Corporation ($111.17) |
| 2017 | $60.66 | 7 | PFIZER INC. ($49.84) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/01/2024 | Medtronic, Inc. | SIGNIA (Device) | Food and Beverage | In-kind items and services | $39.14 | General |
| Category: Surgical Stapling | ||||||
| 09/06/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $7,535.00 | General |
| Category: Oncology | ||||||
| 08/15/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $8,996.00 | General |
| 07/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,355.00 | General |
| Category: ONCOLOGY | ||||||
| 07/29/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Consulting Fee | Cash or cash equivalent | $3,355.00 | General |
| Category: ONCOLOGY | ||||||
| 07/16/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $498.49 | General |
| 07/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $310.25 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $59.77 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $17.27 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $392.87 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $244.70 | General |
| Category: ONCOLOGY | ||||||
| 07/08/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $159.00 | General |
| Category: ONCOLOGY | ||||||
| 02/07/2024 | Janssen Research & Development, LLC | CARVYKTI (Drug) | Consulting Fee | Cash or cash equivalent | $5,525.00 | General |
| Category: Oncology | ||||||
| 12/08/2023 | Acrotech Biopharma Inc. | BELEODAQ (Drug) | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| Category: ONCOLOGY | ||||||
| 03/16/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $7,535.00 | General |
| Category: Oncology | ||||||
| 02/07/2023 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Consulting Fee | Cash or cash equivalent | $6,175.00 | General |
| Category: ONCOLOGY | ||||||
| 11/09/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,850.00 | General |
| 10/18/2022 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $11,050.00 | General |
| 08/31/2022 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $10,791.00 | General |
| 05/17/2022 | Alexion Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $29.61 | General |
| 03/21/2022 | TG Therapeutics, Inc. | UKONIQ (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Hematology | ||||||
| 03/21/2022 | TG Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 09/16/2021 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $4,200.00 | General |
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 01/29/2019 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $11.96 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 115 | 153 | $64,506 | $12,109 |
| 2022 | 6 | 162 | 231 | $86,402 | $17,701 |
| 2021 | 8 | 311 | 572 | $176,103 | $59,987 |
| 2020 | 12 | 456 | 852 | $240,011 | $74,336 |
Total Patients
1,044
Total Services
1,808
Medicare Billing
$164,134
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 40 | 41 | $39,670 | $5,806 | 14.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 43 | $12,134 | $2,843 | 23.4% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2023 | 37 | 42 | $8,435 | $2,365 | 28.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 21 | 27 | $4,267 | $1,095 | 25.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 41 | 41 | $37,506 | $6,526 | 17.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 37 | 95 | $26,009 | $5,532 | 21.3% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 16 | 21 | $8,338 | $1,790 | 21.5% |
| 38222 | Biopsy and aspiration of bone marrow sample for diagnosis | Facility | 2022 | 27 | 28 | $4,937 | $1,789 | 36.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 21 | 21 | $5,778 | $1,270 | 22.0% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 20 | 25 | $3,834 | $794.62 | 20.7% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2021 | 35 | 167 | $27,722 | $26,763 | 96.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 125 | 228 | $73,681 | $17,535 | 23.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 32 | 32 | $29,339 | $5,362 | 18.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 52 | 57 | $12,604 | $2,748 | 21.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 19 | 21 | $10,889 | $2,682 | 24.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 14 | 14 | $9,898 | $2,042 | 20.6% |
| 38222 | Diagnostic aspirations and biopsies of bone marrow | Facility | 2021 | 20 | 23 | $3,960 | $1,485 | 37.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 30 | $8,010 | $1,371 | 17.1% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Facility | 2020 | 51 | 201 | $33,366 | $31,972 | 95.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 133 | 279 | $87,537 | $16,924 | 19.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 33 | 34 | $27,890 | $5,827 | 20.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 34 | 92 | $23,812 | $5,795 | 24.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 73 | 91 | $19,201 | $3,605 | 18.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 23 | 23 | $16,122 | $3,168 | 19.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 13 | 20 | $7,430 | $1,806 | 24.3% |
About Philip Hoffman
Philip Hoffman is a Hematology & Oncology healthcare provider based in Chicago, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1700949229.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Philip Hoffman has received a total of $87,575 in payments from pharmaceutical and medical device companies, with $30,487 received in 2024. These payments were reported across 34 transactions from 14 companies. The most common payment nature is "Consulting Fee" ($85,617).
As a Medicare-enrolled provider, Hoffman has provided services to 1,044 Medicare beneficiaries, totaling 1,808 services with total Medicare billing of $164,134. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Chicago, IL
- Active Since 12/18/2006
- Last Updated 10/24/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1700949229
Products in Payments
- KEYTRUDA (Biological) $7,894
- IMFINZI (Biological) $7,535
- LYNPARZA (Drug) $7,535
- JEMPERLI (Biological) $6,175
- BELEODAQ (Drug) $5,850
- CARVYKTI (Drug) $5,525
- UKONIQ (Drug) $2,700
- KISQALI (Drug) $111.17
- IBRANCE (Drug) $61.88
- SIGNIA (Device) $39.14
- XALKORI (Drug) $11.11
- ZYKADIA (Drug) $10.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Chicago
Michael Bishop
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Young Kwang Chae, Md, Mph, Mba, MD, MPH, MBA
Hematology & Oncology — Payments: $682,642
Hematology & Oncology $682,642
Irfan Mirza, Md, MD
Hematology & Oncology — Payments: $644,273
Hematology & Oncology $644,273
Everett Vokes
Hematology & Oncology — Payments: $449,910
Hematology & Oncology $449,910
Peter Riedell
Hematology & Oncology — Payments: $374,919
Hematology & Oncology $374,919
Rita Nanda
Hematology & Oncology — Payments: $374,678
Hematology & Oncology $374,678